Novartis stock heads into Monday with Kisqali Canada nod and $23 billion U.S. R&D build-out in focus

Novartis closed the day up in Zurich, gaining 0.57% to finish at 119.96 francs, while its U.S. ADRs advanced 1.54%, settling at $156.42.

7 February 2026

Merck stock ends week near highs after Canada clears ENFLONSIA; insider sales surface

Merck & Co., Inc. climbed 1.8% to close at $121.93 Friday, with the stock edging closer to its previous highs. The move followed news that Health Canada cleared the company’s ENFLONSIA RSV antibody for use in newborns and infants.

7 February 2026

NYSE:MRK·Pharmaceuticals·Stock Market

Roche stock price slips into the weekend — here’s what could move shares on Monday

Roche slid 0.64% on Friday to finish at 356.40 Swiss francs, with no new headlines out to move the stock ahead of the weekend. Shares ranged from 352.50 to 357.20 francs, volume landing at roughly 766,000.

7 February 2026

Pharmaceuticals·Stock Market·SWX:ROG

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie finished Friday’s session 2% higher at $223.43, notching a second day in the green while U.S. equities climbed. The stock remains about 9% shy of its 52-week high. Trading volume landed slightly below its recent average.

7 February 2026

Earnings Reports·NYSE:ABBV·Pharmaceuticals·Stock Market

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson stock climbed 0.9% to finish Friday at $239.99, landing close to its intraday peak, after a New Jersey appeals court ejected a major plaintiffs’ firm from part of the company’s talc lawsuits. Roughly 8.3 million shares traded hands.

7 February 2026

NYSE:JNJ·Pharmaceuticals·Stock Market

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly and Company finished Friday’s session $37.34 higher, up 3.7% at $1,058.18 a share.

7 February 2026

NYSE:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant Sciences Ltd shares jumped Friday after the company reported promising mid-stage results for brepocitinib, its immune-modulating drug targeting a rare skin disorder. The update came with the release of the firm’s latest quarterly earnings.

7 February 2026

NASDAQ:ROIV·Pharmaceuticals·Stock Market

Pfizer stock price rises into weekend as FDA priority review, TrumpRx discounts grab focus

Pfizer Inc closed out Friday at $27.22, notching a 2.8% gain. Shares fluctuated from $26.52 to $27.37 throughout the session, with volume hitting roughly 50.7 million shares.

7 February 2026

NYSE:PFE·Pharmaceuticals·Stock Market

GSK share price set for Monday watch after EU clears Nucala COPD use

Shares of GSK ended Friday up 0.83% at 2,198 pence, a 52-week high, after the drugmaker said the European Commission approved Nucala for a form of chronic obstructive pulmonary disease. The stock is up about 17% over the past week and nearly 49% over the past year.

7 February 2026

LSE:GSK.L·Pharmaceuticals·Stock Market

Johnson & Johnson stock rises on talc-court ruling — FDA Class I recall keeps JNJ in focus

Johnson & Johnson shares ticked up on Friday, holding steady into after-hours. Investors weighed a New Jersey court’s latest move in the company’s ongoing talc litigation, along with a new FDA safety notice tied to select devices.

7 February 2026

NYSE:JNJ·Pharmaceuticals·Stock Market

Eli Lilly stock rises after FDA steps up crackdown on GLP-1 copycats

Eli Lilly jumped 3.7% to $1,058.18 in late trading Friday after U.S. regulators moved to clamp down on GLP-1 ingredients in unapproved compounded drugs. The Department of Health and Human Services’ general counsel also referred Hims & Hers, a telehealth firm, to the Justice Department for investigation; Hims tumbled almost 12% postmarket.

7 February 2026

Biotechnology·NYSE:LLY·Pharmaceuticals·Stock Market

Hims & Hers (HIMS) stock slips again as $49 Wegovy copy draws FDA heat and Novo legal threat

Shares of Hims & Hers Health fell roughly 2.6% to $22.88 Friday afternoon, after ranging from $20.95 to $23.61 earlier in the session. That marks the third straight session in the red, following the company’s move to roll out a $49 compounded alternative to Novo Nordisk’s Wegovy weight-loss pill.

6 February 2026

NYSE:HIMS·Pharmaceuticals

Pfizer stock rises as FDA speeds HYMPAVZI review and TrumpRx discounts keep pricing in focus

Pfizer shares climbed 72 cents, or 2.7%, to $27.22 in afternoon trading Friday, outpacing the SPDR S&P 500 ETF’s roughly 1.7% gain. Roughly 30 million Pfizer shares traded hands.

6 February 2026

Healthcare News·NYSE:PFE·Pharmaceuticals·Stock Market

AbbVie stock rises as investors re-rank Rinvoq and Skyrizi after earnings jolt

AbbVie shares rose $4.43, or about 2%, to $223.45 in midday trading on Friday, steadying after a choppy week for large drugmakers. The stock traded between $218.51 and $225.81 earlier in the session.

6 February 2026

Earnings Reports·NYSE:ABBV·Pharmaceuticals·Stock Market

Johnson & Johnson stock ticks up on talc-case ruling as FDA recall adds new wrinkle

Johnson & Johnson shares inched higher on Friday, rising roughly 0.2% to $238.34 around midday, having peaked at $240.22 earlier. This kept the stock just above Thursday’s closing price of $237.79.

6 February 2026

NYSE:JNJ·Pharmaceuticals·Stock Market

Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly and Company shares climbed about 3% on Friday, recovering part of Thursday’s steep 8% drop. The rebound came after the U.S. Food and Drug Administration indicated it would crack down on illegal copycat weight-loss drugs. The stock traded up 3% at $1,051.74. FDA Commissioner Marty Makary emphasized the agency cannot vouch for the “quality, safety or effectiveness” of these non-approved medicines.

6 February 2026

NYSE:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Pfizer stock slips before open as TrumpRx discounts debut and FDA priority review adds a catalyst

Pfizer Inc shares slipped roughly 1.1% to $26.49 in premarket action Friday, following Thursday’s close near $26.79.

6 February 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Shares of Hims & Hers Health dropped 3.8% to $23.48 in premarket trading on Friday. The slide came after FDA Commissioner Marty Makary warned the agency would act quickly against firms mass-marketing “illegal copycat drugs.” The stock had already fallen 3.8% on Thursday and plunged nearly 10% after hours, following Makary’s post on X stating, “The FDA cannot verify the quality, safety, or effectiveness of non-approved drugs.” His comments came after Hims introduced a compounded version of Novo Nordisk’s Wegovy weight-loss medication.

6 February 2026

NASDAQ:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Hims & Hers stock slips premarket after FDA “illegal copycat drugs” warning clouds $49 Wegovy-style pill

Shares of Hims & Hers Health dipped 3.8% to $23.48 in premarket trading Friday, following a tough day on Thursday.

6 February 2026

NYSE:HIMS·NYSE:NVO·Pharmaceuticals·Stock Market

Novo Nordisk stock rebounds as FDA warns on illegal Wegovy copycats

Novo Nordisk A/S shares climbed 4.7% in early trading on Friday after the U.S. Food and Drug Administration pledged to crack down on mass-marketing of unapproved drug copies. By 0848 GMT, the stock was up 4.9% at 294.50 Danish crowns.

6 February 2026

CSE:NOVO-B·Pharmaceuticals·Stock Market

Previous 1 … 14 15 16 17 18 … 49 Next

Merck stock ends week near highs after Canada clears ENFLONSIA; insider sales surface

Roche stock price slips into the weekend — here’s what could move shares on Monday

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Pfizer stock price rises into weekend as FDA priority review, TrumpRx discounts grab focus

GSK share price set for Monday watch after EU clears Nucala COPD use

Johnson & Johnson stock rises on talc-court ruling — FDA Class I recall keeps JNJ in focus

Eli Lilly stock rises after FDA steps up crackdown on GLP-1 copycats

Hims & Hers (HIMS) stock slips again as $49 Wegovy copy draws FDA heat and Novo legal threat

Pfizer stock rises as FDA speeds HYMPAVZI review and TrumpRx discounts keep pricing in focus

AbbVie stock rises as investors re-rank Rinvoq and Skyrizi after earnings jolt

Johnson & Johnson stock ticks up on talc-case ruling as FDA recall adds new wrinkle

Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Pfizer stock slips before open as TrumpRx discounts debut and FDA priority review adds a catalyst

Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers stock slips premarket after FDA “illegal copycat drugs” warning clouds $49 Wegovy-style pill

Novo Nordisk stock rebounds as FDA warns on illegal Wegovy copycats

TechStock² Updates

Keurig Dr Pepper’s $925 Million Chobani Deal Tops 2026 Note Maturities

Alumis Shares Plummet 59% After Lupus Study Failure Wipes Out $1.67 Billion

Ondas Dips 6.1% After Guidance Signals $244 Million Q4 Test

Nasdaq pares decline to 0.8% with $88 oil sustaining rate pressure

Nokia Stock Falls 2.9% as €2.8 Billion AI Orders Face Conversion Test

Dell Shares Drop 3.5% as $60 Billion AI Server Ambition Puts Margins in Focus

Fervo stock surges 24% with $1.1 billion market value boost after Google geothermal agreement

bioAffinity shares jump 45% on CyPath news, trading volume rises to 56 times share count

Nvidia Shares Slip 1.3%, Erasing $69 Billion as Rates Pressure AI Valuations

Nasdaq pares loss to 1.1% amid heavy trading as oil shock rattles markets

Investment Disclaimer